SCHEMBL10175205

SCHEMBL10175205

CCc1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.50
KCNH2 Q12809 8/20 0.49
ADORA2A P29274 5/20 0.44
ADORA1 P30542 5/20 0.44
CYP3A4 P08684 5/20 0.44
ADORA3 P0DMS8 2/20 0.44
NR1H2 P55055 2/20 0.44
NR1H3 Q13133 2/20 0.44
HTT P42858 2/20 0.44
ADORA2B P29275 1/20 0.44
CYP2C19 P33261 1/20 0.44
ABCG2 Q9UNQ0 1/20 0.44
KDM4E B2RXH2 1/20 0.44
NR1I2 O75469 1/20 0.44
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
CYP1A2 P05177 1/20 0.44
HTR1A P08908 1/20 0.44
TSHR P16473 1/20 0.44
CNR1 P21554 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22645629 0.88 KCNH2 (0.49) CYP2D6KCNH2ADORA2AADORA1CYP3A4
SCHEMBL12855189 0.84 CD38 (0.48) CYP2D6KCNH2CYP3A4NR1H2NR1H3
SCHEMBL10311167 0.84 KCNH2 (0.46) CYP2D6KCNH2ADORA2AADORA1CYP3A4
SCHEMBL7219634 0.81 CYP2D6 (0.43) CYP2D6KCNH2ADORA2AADORA1CYP3A4
SCHEMBL7225209 0.79 KCNH2 (0.43) CYP2D6KCNH2ADORA2AADORA1CYP3A4
SCHEMBL1258312 0.79 KCNH2 (0.47) CYP2D6KCNH2ADORA2AADORA1CYP3A4
SCHEMBL2790280 0.79 ALDH1A1 (0.48) CYP2D6KCNH2ADORA2AADORA1CYP3A4
SCHEMBL11893019 0.79 TLR7 (0.55) ADORA2AADORA1ALDH1A1MAPTKMT2A
SCHEMBL2608426 0.78 CYP2D6 (0.46) CYP2D6KCNH2ADORA2AADORA1CYP3A4
SCHEMBL2790491 0.78 KCNH2 (0.46) CYP2D6KCNH2ADORA2AADORA1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012107532-A1 4-AMINOALCOHOLQUINOLINE DERIVATIVES, ENANTIOSELECTIVE SYNTHESIS METHODS AND THE USE THEREOF Université de Picardie Jules Verne (FR) 2012-08-16 WO claimed
US-8163693-B2 Urea-containing peptides as inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2012-04-24 US disclosed
US-20110070168-A1 MACROCYCLIC PEPTIDES AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. (US) 2011-03-24 US disclosed
US-7906619-B2 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2011-03-15 US disclosed
US-20100216725-A1 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. (US) 2010-08-26 US disclosed
US-20100197657-A1 2-ARYL OR HETEROARYL INDOLE DERIVATIVES CHANG RONALD K 2010-08-05 US disclosed
US-7745444-B2 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-06-29 US disclosed
US-20090082261-A1 UREA-CONTAINING PEPTIDES AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. (US) 2009-03-26 US disclosed
US-20090048297-A1 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS (US) 2009-02-19 US disclosed
US-20080311079-A1 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-12-18 US disclosed
US-7378422-B2 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110070168-A1 MACROCYCLIC PEPTIDES AS INHIBITORS OF VIRAL REPLICATION VIP, ZC3HAV1, ZC3HAV1L CYP2D6 1314/4885KCNH2 2022/4885ADORA2A 4149/4885
US-20100197657-A1 2-ARYL OR HETEROARYL INDOLE DERIVATIVES ASIC1, ASIC3, TRPV1 CYP2D6 2014/4885KCNH2 116/4885ADORA2A 612/4885
US-20090082261-A1 UREA-CONTAINING PEPTIDES AS INHIBITORS OF VIRAL REPLICATION VIP, SLC14A1, RPL35 CYP2D6 4255/4885KCNH2 3270/4885ADORA2A 4524/4885
US-20090048297-A1 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION VIP, ZC3HAV1, CCL5 CYP2D6 1609/4885KCNH2 2243/4885ADORA2A 2990/4885
US-20080311079-A1 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease SERPINB1, PRSS1, SPINT2 CYP2D6 1127/4885KCNH2 4716/4885ADORA2A 3751/4885
US-20100216725-A1 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION ZC3HAV1, VIP, O60361 CYP2D6 1625/4885KCNH2 1739/4885ADORA2A 2549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.